When is a marketing application not even worth looking at? For the US Food and Drug Administration (FDA), it's a question with very real implications, both for drugs and medical devices being ...
When a new drug application (NDA) or biologics license application (BLA) is deemed incomplete by the US Food and Drug Administration (FDA), the agency can decide not to review the application. So when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results